Novel Treatments for Hematologic Malignancies: Julie Vose, MD

Video

The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.

This content originally appeared on our sister site, CancerNetwork®.

CancerNetwork® spoke with Julie Vose, MD, MBA, professor, internal medicine, division of oncology and hematology, University of Nebraska Medical Center, about novel options available for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting. She highlighted how these new options can work alone or potentially as part of a combination regimen in future treatment strategies.

Transcript:

The interesting aspects are looking at not only new drugs, new monoclonal antibodies, new CAR T-cells, [or] new bispecific antibodies. Looking at all these different modalities that can be utilized for all different types of hematologic malignancies, either alone or potentially in the future, combined together [is interesting]. We are going to have so many potential treatments that we will be able to [utilize to] help more patients and be able to get these new novel therapies to many more people.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.